Cassava Sciences, Inc. Recorded Big Gain

Cassava Sciences, Inc. (SAVA:NASDAQ) rocketted at $84.4, a gain of 49%. On Wed, Nov 03, 2021, SAVA:NASDAQ touched a New 2-Week Intraday High of $62.74. The stock appeared on our News Catalysts scanner on Thu, Nov 04, 2021 at 04:54 PM in the 'MISCELLANEOUS' category. From Wed, Oct 20, 2021, the stock recorded 40.00% Up Days and 36.36% Green Days

The stock spiked on Thu, Aug 12, 2021 at $126.51 with a volume of 676M+.

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.